OPEN medRxiv : the preprint server for health sciences | 4 Nov 2020
SA Klassen, JW Senefeld, PW Johnson, RE Carter, CC Wiggins, S Shoham, BJ Grossman, JP Henderson, J Musser, E Salazar, WR Hartman, NM Bouvier, STH Liu, LA Pirofski, SE Baker, N van Helmond, RS Wright, D Fairweather, KA Bruno, Z Wang, NS Paneth, A Casadevall and MJ Joyner
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials (RCT), matched-control, case series, and case report studies. Random-effects analyses of RCT data demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
* Data courtesy of Altmetric.com